MammaPrint
70-gene breast-cancer genomic risk classifier with multiple historical/current platform configurations that must remain version scoped.
- Developer
- Agendia
- Intended use
- Risk Stratification
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue
- Molecular modality
- RNA expression
- Current version
- Current MammaPrint FFPE microarray central-laboratory service (2026)
- Evidence context
- 1 structured studies · 0 indexed performance results · 5 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.